Opening stock page...
Fetching company snapshot, pricing, and intelligence.
AI confidence 70% · prior close shown (market closed)
ARGENX SE shows accelerating business momentum based on AlphaOS pipeline evidence, with strong management execution.
Why it matters: Revenue +75% YoY in Q4 FY2025.
1 signal not yet derived from pipeline evidence
What it means for the thesis — synthesis, not a raw event feed.
Pipeline evidence · 0d ago
ARGX's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on ARGX.
Free accounts see more of this; Premium sees all of it.
Updated
What happened recently for ARGENX SE (ARGX) — events, not interpretation.
Research & analysis only — not investment advice.
Held in ETFsweight · est. sleeve dollars
ARGX's AI investment thesis
Upgrade to Premium for ARGX's full multi-agent investment thesis.
Free accounts see more of this; Premium sees all of it.
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Prior close
$972.25
Market cap
$60.17B
Profitable
Yes
Revenue $1.13B
Net income
$344.26M
FY Sep 12, 2026
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for ARGENX SE — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow ARGENX SE through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.
The biggest gains aren't in blockbuster drugs — they're in the infrastructure that makes every drug possible.
The edge in healthcare no longer belongs to the biggest drug pipelines — it belongs to the most targeted ones.
Gene editing and mRNA platforms are moving from research curiosity to approved therapies faster than the market expected.
Breakthroughs in gene editing and targeted therapies are reshaping healthcare landscapes.